Desmopressin

Also known as: DDAVP, Minirin

Desmopressin (DDAVP, Minirin) is a synthetic analog of the antidiuretic hormone arginine vasopressin, with selective agonism at V2 receptors in the renal collecting ducts. This activation increases aquaporin-2 water channel insertion, enhancing water reabsorption and producing concentrated urine. Unlike native vasopressin, desmopressin has minimal V1-receptor activity, reducing vasoconstrictor and pressor effects. Its prolonged half-life (approximately 2–3 hours) and high antidiuretic potency make it suitable for clinical use. Key research findings, supported by over 4,200 PubMed references, demonstrate desmopressin’s efficacy in central diabetes insipidus by correcting polyuria and polydipsia. In nocturnal enuresis, it reduces nighttime urine output, improving dry-night rates in children. Additionally, desmopressin transiently increases plasma levels of von Willebrand factor and factor VIII, making it useful for mild hemophilia A and von Willebrand disease. Studies confirm its safety profile, with hyponatremia being the primary adverse effect, particularly in elderly or fluid-overloaded patients. Clinically, desmopressin is approved for central diabetes insipidus, primary nocturnal enuresis, and as a hemostatic agent in mild bleeding disorders. It is available in oral, intranasal, and injectable formulations. Monitoring serum sodium is recommended during therapy to prevent water intoxication. Desmopressin remains a cornerstone in managing these conditions due to its targeted V2-receptor action and established efficacy. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides